Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson´s disease: drug-induced psychiatric states. En: Weiner WJ, Lang AE, editors. Behavioral Neurology of Movement Disorders. (Advances in Neurology, Vol 65). New York: Raven Press; 1995.

Doraiswamy M, Martin W, Metz A, Deveaugh-Geiss J. Psychosis in Parkinson´s diseases: diagnosis and treatment. Prog Neuro Psychopharmacol Biol Psychiatry 1995;19:835-46.

Marsden CD, Fahn S. Problems in Parkinson´s disease.En: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific; 1981.

Friedman JH. The management of levodopa psychosis. Clin Neuropharmacol 1991;1494:283-95.

Scholz E, Dichgans J. Treatment of drug induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Clin Neuro Sci 1985;235: 60-4.

Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99:S47-S53.

Farde L, Nordstrom AL. Nyberg S, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994;55:S67-S69.

Pfeiffer C, Wagner ML. Clozapine therapy for Parkinson´s disease and other movement disorders. Am J Hosp Pharm 1994;51:3047-53.

Chacón J, Navarro C, Rodríguez E, Alegre S. Tratamiento con clozapina en la enfermedad de Parkinson. En: Alberca R, Ochoa JJ, editores. Pautas actuales en el tratamiento médico y quirúrgico de la enfermedad de Parkinson. Barcelona: Inter-Congrés, Barcelona; 1994.

Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharm Exp Ther 1988;244:685-93.

Alcántara AG, Morcillo L, Barcia D. Risperidona en el tratamiento de trastornos afectivos. An Psiquiatr 1996;12:130-40.

Megens AAHP, Niemegeers CJE, Awouters FHL. Behavioral disinhibition and depression in amphetaminized rats: A comparison of risperidone, ocaperidone and haloperidol. J Pharm Exper Ther 1992;260:160-7.

Casey DE. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 1993;112:S55-S59.

Lee H, Cooney JM, Lawlor BA. The use of risperidone, an atypical neuroleptic, in lewy body disease. Int J Geriatr Psychiatry 1994;9:415-7.

Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinosn´s disease patients. Lancet 1994;343:1370-1.

Allen RL, Walker Z, D´Ath PJ, Katona CLE. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995;346:185.

Damecour CL, Turcotte JR. Therapeutic dilemma: Psychosis and Parkinson´s disease. Can J Psychiatry 1995;40(10):640-1.

Ford B, Lynch T, Greene P. Risperidone in Parkinson´s disease. Lancet 1994;344:681.

McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 1995;346:699.

Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson´s disease and other akunetic-rigid syndromes. J Clin Psychiatry 1995;56(12):556-9.

Wolters ECH, Tuynman-Qua HG. Dopaminomimetic Psychosis: The role of atypical neuroleptics.En: Alberca R, Ochoa JJ, editores. Pautas actuales en el tratamiento médico y quirúrgico de la enfermedad de Parkinson. Barcelona: Inter-Congrés; 1994.

Evatt ML, Jewart D, Juncos JL. "Seroquel" (ICI 204,636) treatment of psychosis in parkinsonism. Mov Disord 1996;11(5):595.

Sanz FJ, Tejadas A, Sartorius N, Hernán Y. Terapia electroconvulsiva en la enfermedad de Parkinson. Psiquiatr Biológica 1995;2(6):225-34.

Barcia D, Martínez F. Cuadros depresivos en la enfermedad de Parkinson tratados con electroshock. Arch Neurobiol 1978;41(5):393-8.

Rasmussen K, Abrams R. Treatment of Parkinson's disease with electroconvulsive therapy. Psychiatr Clin North Am 1991;14(4):925-33.

Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson´s disease with electroconvulsive therapy. Can J Neurol Sci 1988;15:32-4.

Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson´s disease. J Neuropsychiatry Clin Neurosci 1995;7:304-7.

Figiel GS, Hassen MA, Zorumski C, Krishnan KR, Doraiswamy PM, Jarvis MR, Smith DS. ECT-induced delirium in depressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1991;3(4):405-11.

White A, Corn TH, Feetham C, Faulconbridge C. Ondansetron in treatment of schizophrenia. Lancet 1991;337:1173.

Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson´s disease. Lancet 1993;341:562.

Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995;45(7):1305-8.

Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M. Effects of mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacology 1990;5 (2):83-95.

Ikeguchi K, Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatr Clin Neurosci 1995;244(6):320-4.